Updated 7/24/25. The results chart includes audits where the findings have been finalized. Remaining audits are still under review. Information on Corrective Action Plans and Sanctions will be updated once approved by HRSA. HRSA recommends covered entities do not contact audited manufacturers regarding sanctions until a corrective action plan has been approved by HRSA and posted on this website.
Results posted for 5 audits.
| Manufacturer Sort descending | Labeler Codes Reviewed | State | OPA Findings | Sanction | Corrective Action Status |
|---|---|---|---|---|---|
| Biogen U.S. Corp. |
59627 64406 |
MA |
No adverse findings |
None |
N/A Audit closure date: November 2, 2017 |
| EMD Serono, Inc. | 44087 | MA | No adverse findings |
None |
N/A Audit closure date: November 2, 2017 |
| Jacksonville Pharmaceuticals, Inc. | 70003 | FL | No adverse findings |
None |
N/A Audit closure date: July 25, 2017 |
| Pharmacyclics, LLC | 57962 | CA | No adverse findings |
None |
N/A Audit closure date: November 21, 2017 |
| Shire US, Inc. |
42227 47783 59417 54092 58521 66593 68875 64193 00944 |
PA |
No adverse findings |
None |
N/A Audit closure date: July 28, 2017 |
Date Last Reviewed: